Filing Flows › Indivior Pharmaceuticals (INDV) › Q2 2025
Indivior Pharmaceuticals (INDV) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Indivior Pharmaceuticals (INDV) reported revenue of $302M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +14% from the quarter before. Operating margin was 23.8%, net earnings $18.0M (6.0% of revenue).
Indivior Pharmaceuticals, Q2 2025: revenue $302M (+1% year over year), operating margin 23.8%, net earnings $18.0M, operating cash flow $158M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $302M | +14% | +1% |
| Gross profit | $250M | +13% | +14% |
| Operating profit | $72.0M | +9% | — |
| Net earnings | $18.0M | -62% | — |
| Operating cash flow | $158M | +111% | +80% |
| Free cash flow | $141M | +101% | +68% |
What changed
Revenue was $302.0M in Q2 2025, up 1% year over year and up 14% from the previous quarter.
Gross margin was 82.8%, up 9.2 points from a year earlier. Operating profit was $72.0M, a 23.8% margin (up 63.3 points year over year). Operating expenses fell 47% while revenue rose 1%. Net earnings were $18.0M. The effective tax rate was 71.0%.
Operating cash flow was $158.0M (up 80% year over year), 878% of net earnings. Non-cash charges added back $8.0M of share-based compensation. Working capital and other items added $132.0M. Capital expenditures of $17.0M left free cash flow of $141.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the second quarter 2025?
Indivior Pharmaceuticals (INDV) reported revenue of $302M for the second quarter 2025 (Q2 2025), +1% from a year earlier and +14% from the quarter before.
Was Indivior Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $72.0M (23.8% of revenue) and net earnings $18.0M.